Stephen Lucas
Pulmonary Disease · Athens, GANPI 1346235074
Payments from drug & device makers
Across 200 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$388
- Boehringer Ingelheim$385
- Octapharma USA, Inc.$259
- Grifols USA, LLC$187
- Mylan Specialty L.p.$168
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,772100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $1,126 |
| AstraZeneca(2 entities) | 29 | $388 |
| Boehringer Ingelheim | 19 | $385 |
| Octapharma USA, Inc. | 3 | $259 |
| Grifols USA, LLC | 9 | $187 |
| Mylan Specialty L.p. | 10 | $168 |
| Insmed, Inc. | 8 | $144 |
| Mallinckrodt Hospital Products Inc. | 5 | $136 |
| Actelion Pharmaceuticals US, Inc. | 6 | $123 |
| Sanofi | 6 | $109 |
| Harmony Biosciences LLC | 5 | $108 |
| United Therapeutics Corporation | 6 | $106 |
| Johnson & Johnson | 5 | $69 |
| Genentech USA, Inc. | 5 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Baxter Healthcare | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Bayer | 2 | $36 |
| Merck | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Optinose US, Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Pfizer | 1 | $15 |
| AbbVie | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CUTAQUIG$157
- TRELEGY ELLIPTA$103
How this compares
$3,782 in reported general payments places this provider in the 40th percentile of 365 pulmonary disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $23,452 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $17,560 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,930 |
| XareltoRivaroxaban | 22 | $11,389 |
| Levothyroxine Sodium | 113 | $1,156 |
| Lacosamide | 14 | $1,104 |
| Quetiapine Fumarate | 84 | $834 |
| Omeprazole | 78 | $780 |
| Gabapentin | 33 | $768 |
| Haloperidol | 76 | $736 |
| Phenobarbital | 18 | $728 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $642 |
| Atorvastatin Calcium | 46 | $560 |
| Pantoprazole Sodium | 23 | $557 |
| Amlodipine Besylate | 81 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $23,45249 claims |
| GSKTrelegy Ellipta | $1,126 | $17,56023 claims |
| AstraZenecaBreztri Aerosphere | $388 | $11,93019 claims |
| Johnson & JohnsonXarelto | $69 | $11,38922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Athens
- Nehal BhattAthens$371K
- Karan JulkaAthens$94K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.